Effect of EPA/DHA supplementation added on DPP4 inhibitors on lipid and glucose metabolism in patients with type 2 diabetes

Effect of EPA/DHA supplementation added on DPP4 inhibitors on lipid and glucose metabolism in patients with type 2 diabetes - Effect of EPA/DHA supplementation added on DPP4 inhibitors on lipid and glucose metabolism

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011169

Enrollment

Registered

2013-08-01

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

treatment with EPA / DHA supplementation (LOTRIGA &amp

reg

) for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients with type 2 diabetes 2) age 20 years or older 3) treated with DPP4 inhibitor 4) HbA1c >=6.9% 5) TG >=150mg/dl and/or HDL-C <40mg/dl 6) agreed to participate the study

Exclusion criteria

Exclusion criteria: 1) Patients with a history of hypersensitivity to omega-3 fatty acids ethyl 2) Patients who are bleeding (Hemophilia, capillary fragility, gastrointestinal ulcers, urinary tract bleeding, hemoptysis, vitreous hemorrhage, etc.) 3) Patients with severe ketosis or diabetic coma/pre-coma 4) Patients with severe infection, trauma or perioperative period

Design outcomes

Primary

Measure	Time frame
Change in HbA1c , GA , 1,5-AG, TC , TG, LDL-C, HDL-C and FFA	—

Secondary

Measure	Time frame
change in adiponectin, fasting plasma glucose, albuminuria, CRP, proinsulin, insulin, free fatty acid, fatty acid composition, and vascular endothelium function	—

Countries

Japan

Contacts

Public ContactYoshifumi Saisho

Keio University School of Medicine Department of Internal Medicine

ysaisho@z5.keio.jp03-5363-3797

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026